Analytical Data
-
Gene name
DCD
- Application
-
Alternative Names
DCD；AIDD；DSEP；；Dermcidin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P81605
-
Expression Region
20-110aa
-
AA Sequence
YDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKG LDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL
-
Molecular Weight
23 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DCD (Defensin Cationic Peptide) is a type of antimicrobial peptide that plays a crucial role in the innate immune system of various organisms. Research in this area has gained significant attention due to the increasing need for novel antimicrobial agents amidst the rising global threat of antibiotic resistance. DCD proteins are known for their effectiveness against a wide range of pathogens, including bacteria, fungi, and viruses, by disrupting microbial membranes and inhibiting vital cellular processes. The unique structure of DCD, which includes a cationic nature and amphipathic properties, enhances their interaction with negatively charged microbial membranes, making them potent agents for therapeutic applications. Studies have examined the recombinant expression of DCD to produce these peptides in sufficient quantities for further analysis, enabling researchers to explore their mechanisms of action, optimize their antimicrobial efficacy, and evaluate their potential as therapeutic candidates. Additionally, the use of recombinant technology allows for modifications that could improve stability and reduce the likelihood of resistance development. Overall, the investigation of DCD and its recombinant forms holds promise for advancing our understanding of innate immunity and provides innovative strategies for combating infections in a post-antibiotic world.
